SAN DIEGO, Jan. 23, 2018 /PRNewswire/ -- ChemDiv, Inc.
announced at the 36th Annual J.P. Morgan Healthcare
Conference the expansion of its hit identification
collaboration with Janssen Research & Development, LLC
(Janssen) and extending it into finding potent anti-infective drug
candidates. Broadening the original multi-target focus of the
collaboration even further, ChemDiv will use its quarter-century
expertise in early drug discovery and seasoned integrated discovery
platform to deliver a pipeline of novel high-quality hit series in
the area of infectious diseases. Janssen is granted access to
ChemDiv's discovery chemistry platform, while ChemDiv will receive
additional R&D fees and will be eligible for success-based
milestone payments for identification of novel active chemical
series.
"ChemDiv has had a number of highly successful collaborations
with Janssen in multiple therapeutic areas and we are very proud to
see our long-term partnership thrive even further. It showcases our
ability to systematically deliver scientific and commercial value
to industry leaders," comments Rouslan
Michtchenko, Global Head of Business Development at
ChemDiv. "Collaborative risk sharing under this strategic
arrangement fosters R&D productivity, minimizes cost of
acquiring research resources, while appropriately rewarding ChemDiv
based on the productivity of our chemistry. A radical shift from
the traditional unit-pricing models and fee-for-service
arrangements, this model is far more effective as our long-standing
partnership demonstrates – it allows us to continuously deliver
value to our partners, and helps them develop novel effective
treatments for unmet medical needs around the globe."
About ChemDiv and ChemDiv Research Institute:
ChemDiv is a fully integrated discovery and development CRO
serving the life science industry for 27 successful years. The
ChemDiv Research Institute R&D facilities are located at Torrey
Pines Center in San Diego, CA,
ChemRar High-Tech Center and Skolkovo Life Science Cluster in
Moscow. ChemDiv accelerates and
enables pharma and biotech R&D programs from research concepts
to clinic and market registration, covering the complete range of
disciplines, in CNS, oncology, inflammation, cardio metabolic,
infectious diseases, and other therapeutic areas.
Visit www.chemdiv.com for more information.
Media Contact: Ronald
Demuth, rdemuth@chemdiv.com, 858-724-0581
View original content with
multimedia:http://www.prnewswire.com/news-releases/chemdiv-announces-expansion-of-multi-year-hit-identification-collaboration-with-janssen-300586302.html
SOURCE ChemDiv